CRDF
Cardiff Oncology, Inc.Company Information
- Company Name
- Cardiff Oncology, Inc.
- CIK
- CIK0001213037
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CRDF: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- CRDF
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-07-14
- Last sale
- —
- Shares purchased (TTM)
- 1,051,352
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 18,033,222
- Shares outstanding
- 68,397,000
- Ownership
- 26.37%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 3.81%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 9 | 9 | 17 | 10 | 11 | 24 | 51 | 13 | 26 | 19 | 22 | 15 | ||||||
| Short Term Investments | 25 | 38 | 41 | 50 | 60 | 56 | 40 | 45 | 35 | 49 | 53 | 66 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense Current | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 2 | 2 | 2 | ||||||
| Assets Current | 36 | 47 | 60 | 62 | 74 | 83 | 95 | 59 | 62 | 70 | 77 | 84 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 37 | 49 | 62 | 64 | 76 | 85 | 97 | 63 | 66 | 74 | 82 | 88 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 5 | 8 | 2 | 6 | 4 | 5 | 5 | 5 | 5 | 2 | 2 | ||||||
| Accrued Liabilities Current | 6 | 8 | 8 | 12 | 10 | 9 | 8 | 7 | 7 | 6 | 8 | 6 | ||||||
| Operating Lease Liability Current | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 11 | 14 | 16 | 15 | 17 | 13 | 13 | 13 | 13 | 12 | 10 | 9 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Liabilities | 11 | 14 | 16 | 15 | 17 | 14 | 14 | 14 | 14 | 13 | 12 | 11 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 478 | 477 | 475 | 472 | 470 | 468 | 467 | 422 | 413 | 410 | 409 | 408 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -452 | -442 | -430 | -423 | -412 | -398 | -384 | -372 | -361 | -349 | -340 | -330 | ||||||
| Stockholders Equity | 27 | 35 | 45 | 49 | 59 | 71 | 83 | 49 | 52 | 61 | 70 | 78 | ||||||
| Liabilities And Stockholders Equity | 37 | 49 | 62 | 64 | 76 | 85 | 97 | 63 | 66 | 74 | 82 | 88 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Temporary Equity Shares Authorized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Temporary Equity Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Liquidation Preference Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 69 | 68 | 68 | 67 | 67 | 67 | 67 | 49 | 46 | 45 | 45 | 45 | ||||||
| Shares Outstanding | 69 | 68 | 68 | 67 | 67 | 67 | 67 | 49 | 46 | 45 | 45 | 45 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCardiff Oncology, Inc. (CRDF) — SEC Financial Statements & Analysis
Cardiff Oncology, Inc. (CRDF) is a biological products, (no diagnostic substances) company, incorporated in DE. Cardiff Oncology, Inc. trades on Nasdaq as: CRDF. Cardiff Oncology, Inc. (CRDF)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Cardiff Oncology, Inc. carries a market cap of $88.92M, a P/E ratio of -2.22x, a P/B ratio of 3.35x, a P/S ratio of 175.03x, an enterprise value of $79.72M, and an EV/EBITDA multiple of -1.90x. On profitability, it posts an operating margin of -8320.08%, a net margin of -7890.16%, a Return on Equity (ROE) of -94.16%, a Return on Assets (ROA) of -70.90%, and a Return on Invested Capital (ROIC) of -129.69%. Per share, it reports EPS of $-0.59, diluted EPS of $-0.59, free cash flow per share of $-0.60, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -6.79% year-over-year, net income growth of -21.46% year-over-year, and EPS growth of -23.60% year-over-year. On the balance sheet, it maintains a current ratio of 3.30x, a quick ratio of 3.21x, working capital of $24.80M, a debt-to-equity ratio of 0.41x, a debt ratio of 0.29, free cash flow of $-40.92M (TTM), and net debt of $-9.20M. Figures sourced from SEC EDGAR.
- Market Cap
- $88.92M
- P/E TTM
- -2.22x
- EPS TTM
- $-0.59
- P/B TTM
- 3.35x
- ROE TTM
- -94.16%
- ROA TTM
- -70.90%
- Debt To Equity
- 0.41x
- Free Cash Flow TTM
- $-40.92M
- Net Revenue TTM Growth 1Y
- -6.79%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Cardiff Oncology, Inc. in?
Cardiff Oncology, Inc. (CRDF) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does CRDF trade on?
Cardiff Oncology, Inc. (CRDF) trades on the Nasdaq.
Where is Cardiff Oncology, Inc. incorporated?
Cardiff Oncology, Inc. is incorporated in DE.
When was Cardiff Oncology, Inc. (CRDF)'s most recent SEC filing?
Cardiff Oncology, Inc. (CRDF)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is CRDF's market cap?
Cardiff Oncology, Inc. (CRDF) has a market capitalization of $88.92M as of 2026-06-30.
What is CRDF's EPS (earnings per share)?
Cardiff Oncology, Inc. (CRDF)'s trailing twelve month EPS is $-0.59 as of 2026-06-30.
What is CRDF's ROE (return on equity)?
Cardiff Oncology, Inc. (CRDF)'s trailing twelve month Return on Equity (ROE) is -94.16% as of 2026-06-30.
What is CRDF's ROA (return on assets)?
Cardiff Oncology, Inc. (CRDF)'s trailing twelve month Return on Assets (ROA) is -70.90% as of 2026-06-30.
What is CRDF's ROIC (return on invested capital)?
Cardiff Oncology, Inc. (CRDF)'s trailing twelve month Return on Invested Capital (ROIC) is -129.69% as of 2026-06-30.
What is CRDF's EV/EBITDA?
Cardiff Oncology, Inc. (CRDF)'s trailing twelve month EV/EBITDA is -1.90x as of 2026-06-30.